Please wait a minute...
文章检索
预防医学  2025, Vol. 37 Issue (8): 858-863    DOI: 10.19485/j.cnki.issn2096-5087.2025.08.021
  妇幼保健 本期目录 | 过刊浏览 | 高级检索 |
先天性甲状腺功能减退症患儿年龄别体质指数Z评分变化轨迹及影响因素
成灵灵1, 阎亚琼1,2, 白增华2, 张晓刚2, 郝丽婷2, 杨慧莹1
1.山西医科大学公共卫生学院,山西 太原 030001;
2.山西省儿童医院(山西省妇幼保健院),山西 太原 030013
Trajectories of body mass index for age z-score and its influencing factors among children with congenital hypothyroidism
CHENG Lingling1, YAN Yaqiong1,2, BAI Zenghua2, ZHANG Xiaogang2, HAO Liting2, YANG Huiying1
1. School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, China;
2. Shanxi Children's Hospital (Shanxi Maternal and Child Health Hospital), Taiyuan, Shanxi 030013, China
全文: PDF(872 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 基于潜类别增长模型(LCGM)分析0~3岁先天性甲状腺功能减退症(CH)患儿年龄别体质指数Z评分(BAZ)变化轨迹及其影响因素,为完善CH患儿治疗措施、优化生长管理提供依据。方法 选择2017—2022年山西省儿童医院(山西省妇幼保健院)新生儿疾病筛查中心0~3岁CH患儿为研究对象,回顾性收集基本信息、3~36月龄身高和体重、开始治疗年龄、确诊时促甲状腺激素(TSH)水平和家庭信息等资料。按世界卫生组织儿童体格发育标准,计算各月龄患儿BAZ;采用LCGM分析BAZ变化轨迹,采用无序多分类logistic回归模型分析CH患儿BAZ变化轨迹的影响因素。结果 纳入299例CH患儿,其中男童140例,占46.82%;女童159例,占53.18%。BAZ MQR)为0.50(1.68)。LCGM分析分为持续高生长模式组,24例占8.03%;较慢生长模式组,39例占13.04%;适宜生长模式组,236例占78.93%。无序多分类logistic回归分析结果显示,相较于适宜生长模式CH患儿,开始治疗年龄为30~60 d(OR=0.109,95%CI:0.016~0.732;OR=0.166,95%CI:0.032~0.852)的CH患儿持续高生长模式和较慢生长模式风险较低;确诊时TSH水平为50~150 mIU/L(OR=3.554,95%CI:1.201~10.514)、父亲文化程度为高中/中专(OR=2.975,95%CI:1.003~8.823)的CH患儿持续高生长模式风险较高,父亲生育年龄为30~35岁(OR=0.166,95%CI:0.034~0.806)的CH患儿持续高生长模式风险较低。结论 0~3岁CH患儿BAZ变化轨迹呈现持续高生长模式、较慢生长模式和适宜生长模式3组,其中持续高生长模式、较慢生长模式与治疗时机、确诊时TSH水平、父亲生育年龄和文化程度有关,建议加强早期治疗干预和家庭随访指导。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
成灵灵
阎亚琼
白增华
张晓刚
郝丽婷
杨慧莹
关键词 年龄别体质指数Z评分先天性甲状腺功能减退症潜类别增长模型影响因素    
AbstractObjective To analyze the trajectories of body mass index for age z-score (BAZ) and its influencing factors among children with congenital hypothyroidism (CH) based on latent class growth modeling (LCGM), so as to provide the evidence for improving treatment measures and optimizing growth management among children with CH. Methods Children with CH aged 0 to 3 years from the Newborn Disease Screening Center of Shanxi Children's Hospital (Shanxi Maternal and Child Health Hospital) between 2017 and 2022 were selected as the research subjects. Basic information, height and weight data from 3 to 36 months of age, age at treatment initiation, thyroid-stimulating hormone (TSH) levels at diagnosis, and family information were retrospectively collected. BAZ for children with CH at each month of age was calculated based on the WHO Child Growth Standards. The trajectories of BAZ were analyzed using LCGM, and factors affecting the trajectories of BAZ among children with CH were analyzed using a multinomial logistic regression model. Results A total of 299 children with CH were included. There were 140 boys (46.82%) and 159 girls (53.18%). The median of BAZ was 0.50 (interquartile range, 1.68). The LCGM analysis categorized the subjects into three groups: the persistent high-growth pattern group with 24 cases (8.03%), the slow-growth pattern group with 39 cases (13.04%), and the appropriate-growth pattern group with 236 cases (78.93%). Multinomial logistic regression analysis showed that compared to the children with CH in the appropriate-growth pattern group, those who started treatment at the age of 30 to 60 days (OR=0.109, 95%CI: 0.016-0.732; OR=0.166, 95%CI: 0.032-0.852) had a lower risk of persistent high-growth and slow-growth patterns; CH children with TSH levels of 50 to 150 mIU/L at diagnosis (OR=3.554, 95%CI: 1.201-10.514) and those whose paternal had a senior high school/technical secondary school education (OR=2.975, 95%CI: 1.003-8.823) exhibited a higher risk of the persistent high-growth pattern. Conversely, CH children whose paternal reproductive age was 30 to 35 years (OR=0.166, 95%CI: 0.034-0.806) had a lower risk of the persistent high-growth pattern. Conclusions The BAZ trajectory of children with CH aged 0 to 3 years exhibited three patterns: persistent high-growth, slow-growth, and appropriate-growth. The persistent high-growth and slow-growth patterns were associated with treatment timing, TSH levels at diagnosis, paternal reproductive age, and paternal education level. It is recommended to strengthen early treatment interventions and provide family follow-up guidance.
Key wordsbody mass index for age z-score    congenital hypothyroidism    latent class growth model    influencing factor
收稿日期: 2025-05-26      修回日期: 2025-07-29      出版日期: 2025-08-10
中图分类号:  R725.8  
基金资助:山西省科技厅软科学研究项目(2018041035-2)
作者简介: 成灵灵,硕士研究生在读,公共卫生专业
通信作者: 阎亚琼,E-mail:yangyq1968@163.com   
引用本文:   
成灵灵, 阎亚琼, 白增华, 张晓刚, 郝丽婷, 杨慧莹. 先天性甲状腺功能减退症患儿年龄别体质指数Z评分变化轨迹及影响因素[J]. 预防医学, 2025, 37(8): 858-863.
CHENG Lingling, YAN Yaqiong, BAI Zenghua, ZHANG Xiaogang, HAO Liting, YANG Huiying. Trajectories of body mass index for age z-score and its influencing factors among children with congenital hypothyroidism. Preventive Medicine, 2025, 37(8): 858-863.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2025.08.021      或      http://www.zjyfyxzz.com/CN/Y2025/V37/I8/858
[1] CHERELLA C E,WASSNER A J.Congenital hypothyroidism:insights into pathogenesis and treatment[J/OL].Int J Pediatr Endocrinol,2017[2025-07-29].https://doi.org/10.1186/s13633-017-0051-0.
[2] NAZARI J,JAFARI K,CHEGINI M,et al.Physical and mental growth and development in children with congenital hypothyroidism:a case-control study[J].Orphanet J Rare Dis,2021,16(1):1-9.
[3] FREEDMAN D S,DAVIES A J G,KOMPANIYETS L,et al.A longitudinal comparison of alternatives to body mass index z-scores for children with very high body mass indexes[J].J Pediatr,2021,235:156-162.
[4] NASCIMENTO H,CATARINO C,MENDONÇA D,et al.Comparison between CDC and WHO BMI z-score and their relation with metabolic risk markers in Northern Portuguese obese adolescents[J].Diabetol Metab Syndr,2015,7:1-5.
[5] BAUER A J,WASSNER A J.Thyroid hormone therapy in congenital hypothyroidism and pediatric hypothyroidism[J].Endocrine,2019,66(1):51-62.
[6] STOUPA A,KARIYAWASAM D,POLAK M,et al.Genetics of congenital hypothyroidism:modern concepts[J].Pediatr Investig,2022,6(2):123-134.
[7] VAN TROTSENBURG P,STOUPA A,LÉGER J,et al.Congenital hypothyroidism:a 2020-2021 consensus guidelines update-an ENDO-European reference network initiative endorsed by the European society for pediatric endocrinology and the European society for endocrinology[J].Thyroid,2021,31(3):387-419.
[8] 中华人民共和国卫生部.卫生部关于印发《新生儿疾病筛查技术规范(2010年版)》的通知[J].中华人民共和国卫生部公报,2011(1):12-22.
[9] WHO Multicentre Growth Reference Study Group.WHO Child Growth Standards based on length/height,weight and age[J].Acta Paediatr Suppl,2006,450:76-85.
[10] 冯国双,于石成,刘世炜.轨迹分析模型在追踪数据分析中的应用[J].中国预防医学杂志,2014,15(3):292-295.
FENG G S,YU S C,LIU S W.Application of trajectory analysis model in tracking data analysis[J].Chin Prev Med,2014,15(3):292-295.(in Chinese)
[11] NGUENA NGUEFACK H L,PAGÉM G,KATZ J,et al.Trajectory modelling techniques useful to epidemiological research:a comparative narrative review of approaches[J].Clin Epidemiol,2020,12:1205-1222.
[12] VAN DER NEST G,LIMA PASSOS V,CANDEL M J J M,et al.An overview of mixture modelling for latent evolutions in longitudinal data:modelling approaches,fit statistics and software[J/OL].Adv Life Course Res,2020,43.[2025-07-29].https://doi.org/10.1016/j.alcr.2019.100323.
[13] VAN DE SCHOOT R,SIJBRANDIJ M,WINTER S D,et al.The GRoLTS-checklist:guidelines for reporting on latent trajectory studies[J].Struct Equ Model A Multidiscip J,2017,24(3):451-467.
[14] 郑新灵,黄凌飞.86 144名新生儿先天性甲状腺功能低下症筛查结果[J].浙江预防医学,2014,26(6):618-619,626.
ZHENG X L,HUANG L F.Screening results of congenital hypothyroidism in 86 144 newborns[J].China Prev Med J,2014,26(6):618-619,626.(in Chinese)
[15] CAMMISA I,RIGANTE D,CIPOLLA C.Growth outcomes and final height in children with acquired hypothyroidism:a systematic review[J].Children(Basel),2024,11(12):1-13.
[16] SCHUMAKER T,CENSANI M.Growth failure and excessive weight gain in a 10 year old male with obesity:approach to diagnosis,management,and treatment of acquired hypothyroidism[J].Front Pediatr,2018,6:1-4.
[17] CALCATERRA V,MAGENES V C,SICCARDO F,et al.Thyroid dysfunction in children and adolescents affected by undernourished and overnourished eating disorders[J].Front Nutr,2023,10:1-11.
[1] 翟羽佳, 章涛, 古雪, 徐乐, 吴梦娜, 林君芬, 吴晨. 社区老年人认知衰弱现况调查[J]. 预防医学, 2025, 37(8): 762-766,772.
[2] 苏德华, 陈向阳, 李君, 赵丽娜, 张鹤美, 朱婷婷, 胡文雪, 赖江宜. 温州市新报告HIV/AIDS病例抗病毒治疗及时性分析[J]. 预防医学, 2025, 37(8): 804-808.
[3] 严青秀, 王炜, 郝晓刚, 高宇, 方春福, 张幸, 刘文峰. 2017—2023年衢州市肺结核患者未收治情况分析[J]. 预防医学, 2025, 37(8): 799-803.
[4] 王晓宇, 张志平, 董玉颖, 梁杰, 陈强. 老年人带状疱疹疫苗接种意愿的影响因素分析[J]. 预防医学, 2025, 37(8): 809-813.
[5] 王海琪, 张涵潇, 杨凤云, 国献丽, 范生荣, 张丽锋, 蒋泓. 嘉定区中学生抑郁情绪调查[J]. 预防医学, 2025, 37(8): 832-836.
[6] 何欢, 赵雪, 蔡鹏, 詹小亚, 马蕾. 老年慢性阻塞性肺疾病患者运动恐惧的影响因素研究[J]. 预防医学, 2025, 37(7): 659-663.
[7] 汪小梅, 郑杉, 翁晓飞. 慢性阻塞性肺疾病患者二元应对水平的影响因素分析[J]. 预防医学, 2025, 37(7): 664-667,672.
[8] 王立新, 王浩, 何青芳, 方雨葭, 张洁, 杜晓甫. 浙江省居民限盐勺使用情况调查[J]. 预防医学, 2025, 37(7): 668-672.
[9] 林飞云, 周敏聪, 陈晓雯. 高龄经产妇产后抑郁症状及影响因素分析[J]. 预防医学, 2025, 37(7): 732-736.
[10] 陈强, 郭震, 朱玮, 何晓庆, 朱斌斌. 金华市重点人群职业健康素养调查[J]. 预防医学, 2025, 37(7): 747-750,756.
[11] 俞丹丹, 杨加丽, 张雅萍, 许慧琳, 何丹丹, 李俊. 2型糖尿病共病患者空腹血糖波动轨迹的影响因素研究[J]. 预防医学, 2025, 37(6): 562-567,572.
[12] 白茂潮, 李芬, 地力努尔·吐尔逊, 热米拉·热扎克, 王岩. HPV感染女性焦虑症状的影响因素分析[J]. 预防医学, 2025, 37(6): 573-577,582.
[13] 杨雨欣, 邵银燕, 李艳娟. 中医养生保健素养及影响因素研究进展[J]. 预防医学, 2025, 37(6): 577-582.
[14] 李美琳, 周梦姣, 吴佳芸, 喻喆, 孔利萍. 老年男性2型糖尿病患者合并肌少症的影响因素分析[J]. 预防医学, 2025, 37(6): 588-592.
[15] 梁茵茵, 袁瑞, 刘光涛, 李辉, 付云. 湖州市中学生抑郁症状现况调查[J]. 预防医学, 2025, 37(6): 622-627,631.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed